Journal
ONCOTARGET
Volume 7, Issue 3, Pages 2585-2595Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.6226
Keywords
ATP1B1; expression; prognosis; CN-AML
Categories
Funding
- National Natural Science Foundation of China [61501519, 81500118, 61372047 61372047]
- National High-tech R&D Program of China [2013BAI03B04]
- Chinese PLA General Hospital Nursery Foundation [14KMM38]
Ask authors/readers for more resources
ATP1B1 encodes the Na, K-ATPase beta subunit, a key regulator of the Na+ and K+ electrochemical gradients across the plasma membrane and an essential regulator of cellular activity. We used several microarray datasets to test the prognostic efficacy of ATP1B1 expression in cytogenetically normal acute myeloid leukemia (CN-AML). Within the primary cohort (n = 157), high ATP1B1 expression (ATP1B1(high)) was associated with shorter overall survival (OS) and event-free survival (EFS) (P = 0.0068, P = 0.0039, respectively). Similar results were also obtained in the European Leukemia Net (ELN) Intermediate-I genetic category (OS: P = 0.0035, EFS: P = 0.0007). Multivariable analyses confirmed ATP1B1(high) is an independent predictor of shorter OS (P = 0.042) and EFS (P = 0.035). Analysis of another CN-AML cohort confirmed that ATP1B1(high) is associated with shorter OS (P = 0.0046, n = 162). In addition, up-regulation of oncogenes/onco-microRNAs such as MYCN, CCND2, CDK6, KIT and miR-155, among others, was associated with ATP1B1(high), which may be indicative of ATP1B1's leukemogenicity. Our results may improve risk stratification and indicate new therapeutic targets for CN-AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available